Are circulating tumor cells an independent prognostic factor in patients with high-risk melanoma?

2004 ◽  
Vol 1 (2) ◽  
pp. 74-75 ◽  
Author(s):  
Dave SB Hoon
Keyword(s):  
High Risk ◽  
Prognostic Factor ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Independent Prognostic Factor ◽  
High Risk Melanoma ◽  
Risk Melanoma

Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma

2004 ◽  
Vol 111 (5) ◽  
pp. 741-745 ◽  
Author(s):  
Simone Mocellin ◽  
Paolo Del Fiore ◽  
Laura Guarnieri ◽  
Romano Scalerta ◽  
Mirto Foletto ◽  
...  
Keyword(s):  
High Risk ◽  
Prognostic Factor ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cutaneous Melanoma ◽  
Molecular Detection ◽  
Independent Prognostic Factor

968 PROGNOSTIC FACTOR OF CIRCULATING TUMOR CELLS IN HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER

2010 ◽  
Vol 183 (4S) ◽  
Author(s):  
Ettore De Berardinis ◽  
Gian Maria Busetto ◽  
Alessandro Sciarra ◽  
Cristiano Cristini ◽  
Francesco Minisola ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Prognostic Factor ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

scholarly journals Canadian Melanoma Conference Recommendations on High-Risk Melanoma Surveillance: A Report from the 14th Annual Canadian Melanoma Conference; Banff, Alberta; 20–22 February 2020

2021 ◽  
Vol 28 (3) ◽  
pp. 2040-2051
Author(s):  
Christina W. Lee ◽  
J. Gregory McKinnon ◽  
Noelle Davis
Keyword(s):  
High Risk ◽  
Brain Magnetic Resonance Imaging ◽  
Initial Therapy ◽  
Expert Opinions ◽  
High Risk Melanoma ◽  
Novel Approach ◽  
Positron Emission ◽  
Risk Melanoma ◽  
National Expert ◽  
Melanoma Surveillance

Introduction: There are a lack of established guidelines for the surveillance of high-risk cutaneous melanoma patients following initial therapy. We describe a novel approach to the development of a national expert recommendation statement on high-risk melanoma surveillance (HRS). Methods: A consensus-based, live, online voting process was undertaken at the 13th and 14th annual Canadian Melanoma Conferences (CMC) to collect expert opinions relating to “who, what, where, and when” HRS should be conducted. Initial opinions were gathered via audience participation software and used as the basis for a second iterative questionnaire distributed online to attendees from the 13th CMC and to identified melanoma specialists from across Canada. A third questionnaire was disseminated in a similar fashion to conduct a final vote on HRS that could be implemented. Results: The majority of respondents from the first two iterative surveys agreed on stages IIB to IV as high risk. Surveillance should be conducted by an appropriate specialist, irrespective of association to a cancer centre. Frequency and modality of surveillance favoured biannual visits and Positron Emission Tomography Computed Tomography (PET/CT) with brain magnetic resonance imaging (MRI) among the systemic imaging modalities available. No consensus was initially reached regarding the frequency of systemic imaging and ultrasound of nodal basins (US). The third iterative survey resolved major areas of disagreement. A 5-year surveillance schedule was voted on with 92% of conference members in agreement. Conclusion: This final recommendation was established following 92% overall agreement among the 2020 CMC attendees.

Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma

2009 ◽  
Vol 27 (25) ◽  
pp. e82-e83 ◽  
Author(s):  
Sanjiv S. Agarwala ◽  
Robert J. Gray ◽  
Michael K.K. Wong
Keyword(s):  
High Risk ◽  
Interferon Alfa ◽  
High Dose ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
High Dose Interferon

The p.G23S CDKN2A founder mutation in high-risk melanoma families from Central Italy

2007 ◽  
Vol 17 (6) ◽  
pp. 387-392 ◽  
Author(s):  
Francesca Gensini ◽  
Roberta Sestini ◽  
Mauro Piazzini ◽  
Marina Vignoli ◽  
Alessandra Chiarugi ◽  
...  
Keyword(s):  
High Risk ◽  
Founder Mutation ◽  
Central Italy ◽  
High Risk Melanoma ◽  
Risk Melanoma
Sign in / Sign up

Export Citation Format

Share Document